Damora Therapeutics annual net debt
2019
2020
2021
2022
2023
2024
2025
Damora Therapeutics Net Debt Growth & History (DMRA)
Damora Therapeutics's net debt was −$257.6M for fiscal 2025.
View full Damora Therapeutics company overviewDamora Therapeutics annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$257.6M | −$243.5M | — |
| 2024 | 2024-12-31 | −$14.1M | $7.1M | — |
| 2023 | 2023-12-31 | −$21.2M | $10.8M | — |
| 2022 | 2022-12-31 | −$32.0M | $29.7M | — |
| 2021 | 2021-12-31 | −$61.7M | $101.0M | — |
| 2020 | 2020-12-31 | −$162.7M | −$151.7M | — |
| 2019 | 2019-12-31 | −$11.0M | — | — |
Damora Therapeutics quarterly net debt
Q4.19
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | −$257.6M | −$243.5M | — |
| Q3 2025 | 2025-09-30 | −$7.5M | $12.1M | — |
| Q2 2025 | 2025-06-30 | −$10.1M | $12.6M | — |
| Q1 2025 | 2025-03-31 | −$11.9M | $9.1M | — |
| Q4 2024 | 2024-12-31 | −$14.1M | $7.1M | — |
| Q3 2024 | 2024-09-30 | −$19.6M | $3.0M | — |
| Q2 2024 | 2024-06-30 | −$22.8M | −$455,000 | — |
| Q1 2024 | 2024-03-31 | −$20.9M | $3.4M | — |
| Q4 2023 | 2023-12-31 | −$21.2M | $10.8M | — |
| Q3 2023 | 2023-09-30 | −$22.6M | $4.9M | — |
| Q2 2023 | 2023-06-30 | −$22.3M | $6.5M | — |
| Q1 2023 | 2023-03-31 | −$24.4M | $20.3M | — |
| Q4 2022 | 2022-12-31 | −$32.0M | $29.7M | — |
| Q3 2022 | 2022-09-30 | −$27.5M | $37.7M | — |
| Q2 2022 | 2022-06-30 | −$28.8M | $38.7M | — |
| Q1 2022 | 2022-03-31 | −$44.7M | $28.6M | — |
| Q4 2021 | 2021-12-31 | −$61.7M | $101.0M | — |
| Q3 2021 | 2021-09-30 | −$65.2M | $19.2M | — |
| Q2 2021 | 2021-06-30 | −$67.5M | — | — |
| Q1 2021 | 2021-03-31 | −$73.3M | — | — |
| Q4 2020 | 2020-12-31 | −$162.7M | −$151.7M | — |
| Q3 2020 | 2020-09-30 | −$84.4M | — | — |
| Q4 2019 | 2019-12-31 | −$11.0M | — | — |
Damora Therapeutics net debt trends
Over the last five fiscal years, Damora Therapeutics's net debt decreased from −$162.7M to −$257.6M, a change of −$94.9M. The latest reported quarter, Q4 2025, shows −$257.6M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Damora Therapeutics source filings ↗